ACUTAAS vs CORONA: Stock Comparison
ACUTAAS CHEMICALS is the larger company by market capitalisation. ACUTAAS CHEMICALS shows faster revenue growth, lower leverage and a higher ROCE, while CORONA REMEDIES shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
ACUTAAS leads 8; CORONA leads 3 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | ACUTAAS | CORONA |
|---|---|---|
| Sector | Healthcare | — |
| Industry | Pharmaceuticals | — |
Price
| Metric | ACUTAAS | CORONA |
|---|---|---|
| Live Price | ₹3,253.4 | ₹2,010 |
| Day Change | 1.48% | 0.3% |
| Volume | 5.57 L | 17,444 |
| 52-Week High | ₹3,740 | ₹2,292.4 |
| 52-Week Low | ₹1,570 | ₹1,336.6 |
| Distance from 52W High | -13.01% | -12.32% |
Valuation
| Metric | ACUTAAS | CORONA |
|---|---|---|
| Market Cap | ₹26,63,595.08 L Cr | ₹12,313 Cr |
| P/E Ratio | 69.01x | 61.87x |
| P/B Ratio | 16.12x | 16.49x |
| EPS | ₹47 | ₹9.83 |
| Book Value | ₹201.93 | ₹122.12 |
| Dividend Yield | 0.08% | 0.5% |
Growth
| Metric | ACUTAAS | CORONA |
|---|---|---|
| Revenue Growth (TTM YoY) | 40.3% | 0% |
| EPS Growth (TTM YoY) | 105.6% | 0% |
| Qtr Sales Growth | 0% | 0% |
| Qtr Profit Growth | 0% | 0% |
Profitability & Leverage
| Metric | ACUTAAS | CORONA |
|---|---|---|
| ROE | 21.95% | 24.28% |
| ROCE | 24.04% | 20.94% |
| Net Margin | 26.6% | 13.19% |
| Operating Margin | 37.46% | 15.89% |
| Debt to Equity | 0.01x | 0.19x |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | ACUTAAS | CORONA |
|---|---|---|
| Promoter Holding | 32.66% | 69% |
| FII Holding | 22.62%▲ 1.01 pp | 4.21%▲ 0.58 pp |
| DII Holding | 19.4%▼ 0.16 pp | 16.45%▲ 3.55 pp |
| Public Holding | 25.31%▼ 0.85 pp | 10.34%▼ 4.14 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: ACUTAAS CHEMICALS and CORONA REMEDIES.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.